Needham & Company Assumes Coverage on Pharmacyclics (PCYC) at Buy; Review and ASH Meeting Preview

November 11, 2011 9:09 AM EST
Get Alerts PCYC Hot Sheet
Price: $261.25 --0%

Rating Summary:
    7 Buy, 19 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 35 | Down: 25 | New: 13
Trade PCYC Now!
Join SI Premium – FREE
Needham & Company assumes coverage on Pharmacyclics (NASDAQ: PCYC) with a Buy. PT $14.00.

Needham analyst says, "Pharmacyclics is developing PCI-32765, a small molecule Btk inhibitor, for the treatment of B-cell related cancers. Data from a collection of open-label Phase 1/2 trials have pointed to impressive efficacy as well as an encouraging safety profile. The company is focusing initially on relapsed/refractory (r/r) Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), with plans to ultimately expand to a broader front-line Non-Hodgkin’s Lymphoma label."

For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.

Shares of Pharmacyclics closed at $11.10 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Related Entities

Needham & Company

Add Your Comment